BioSpace News Archive

Drug Development

Adaptimmune Secures up to $125 Million Debt Financing with Hercules Capital

Philadelphia, Pennsylvania and Oxford, United Kindgom--(Newsfile Corp. - May 15, 2024) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a company redefining the treatment of solid tumor cancers with cell therapy, today announced that...

May 15, 2024
·
4 min read
Business

Adaptimmune Reports Q1 2024 Financial and Business Updates

Afami-cel commercial and regulatory update presented at Company’s Investor Day (replay HERE); FDA review and inspections progressing with PDUFA date of August 4th, 2024

May 15, 2024
·
13 min read
Drug Development

Bayer Starts Phase I Study With Novel Targeted Radionuclide Therapy 225Ac-PSMA-Trillium in Advanced Metastatic Prostate Cancer

Bayer announced today initiation of dosing in a Phase I first-in-human clinical study with 225Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy.

May 15, 2024
·
5 min read
AquaBounty Technologies Announces First Quarter 2024 Financial Results

Harvard, Massachusetts--(Newsfile Corp. - May 15, 2024) - AquaBounty Technologies, Inc. (NASDAQ: AQB) (“AquaBounty” or the “Company”), a land-based aquaculture company utilizing technology to enhance productivity and sustainability, today announced...

May 15, 2024
·
13 min read
AmacaThera doses First In Human Study to Evaluate, AMT-143, for Non-opioid Treatment of Post-operative Pain

AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company’s lead asset in non-opioid acute pain management.

May 15, 2024
·
2 min read
FinalSpark Launches the First Remote Research Platform Using Human Neurons for Biocomputing

FinalSpark, a pioneering Swiss biocomputing startup, has launched the first-ever online platform enabling global researchers to conduct experiments remotely on biological neurons in vitro.

May 15, 2024
·
2 min read
Pharm Country

Women in U.S. Can Now Collect Their Own Sample for Cervical Cancer Screening

BD, a leading global medical technology company, announced U.S. Food and Drug Administration approval for the use of self-collected vaginal specimens for human papillomavirus testing when cervical specimens cannot otherwise be obtained.

May 15, 2024
·
5 min read
Drug Development

Ocugen Announces Dosing Completion of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy

Ocugen, Inc. announced that dosing is complete in the second cohort of its Phase 1/2 GARDian clinical trial for OCU410ST —a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment for life.

May 15, 2024
·
5 min read
Business

DarioHealth Reports First Quarter 2024 Financial and Operating Results

DarioHealth Corp., a leader in the global digital health market, reported financial results for the first quarter 2024.

May 15, 2024
·
26 min read
Pharm Country

Merck to Present New Data at 2024 ASCO Annual Meeting Demonstrating Advancements in Novel Oncology Treatment Approaches Across Broad Portfolio and Diverse Pipeline

Merck, known as MSD outside of the United States and Canada, announced that new data for four approved oncology medicines and four pipeline candidates in more than 25 types of cancer will be presented at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago from May 31-June 4.

May 15, 2024
·
79 min read